Associated Papers
Blood-Based Genomic Alteration Signature for Predicting Progression-Free Survival in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Real-World Study.
Wang R et al.
Cancer Research Communications, 2025
A structurally informed human protein-protein interactome reveals proteome-wide perturbations caused by disease mutations.
Xiong D et al.
Nature Biotechnology, 2025
Sequence rules for a long SPOP-binding degron required for protein ubiquitylation.
Makhlouf L et al.
The Biochemical Journal, 2025
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
SPOP point mutations regulate substrate preference and affect its function.
Deng Y et al.
Cell Death & Disease, 2024
Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.
Wang R et al.
Cancer Research Communications, 2023
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer.
Stangl A et al.
The Prostate, 2023
Mass spectrometry-based targeted proteomics for analysis of protein mutations.
Lin TT et al.
Mass Spectrometry Reviews, 2023
CHD1, a multifaceted epigenetic remodeler in prostate cancer.
Li H et al.
Frontiers in Oncology, 2023
Whole-exome Sequencing of Nigerian Prostate Tumors from the Prostate Cancer Transatlantic Consortium (CaPTC) Reveals DNA Repair Genes Associated with African Ancestry.
White JA et al.
Cancer Research Communications, 2022
SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer.
Shi Q et al.
Cell Death and Differentiation, 2022
UbE3-APA: a bioinformatic strategy to elucidate ubiquitin E3 ligase activities in quantitative proteomics study.
Gong Y et al.
Bioinformatics (oxford, England), 2022
Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L et al.
Cancer Research, 2021
2-kupl: mapping-free variant detection from DNA-seq data of matched samples.
Wang Y et al.
Bmc Bioinformatics, 2021
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Tsui DWY et al.
Genome Medicine, 2021
Extreme value theory as a framework for understanding mutation frequency distribution in cancer genomes.
Tokutomi N et al.
Plos One, 2021
Manipulation of Developmental Gamma-Globin Gene Expression: an Approach for Healing Hemoglobinopathies.
Venkatesan V et al.
Molecular and Cellular Biology, 2020
The Roles of SPOP in DNA Damage Response and DNA Replication.
Maekawa M et al.
International Journal of Molecular Sciences, 2020
Somatic Evolution in Non-neoplastic IBD-Affected Colon.
Olafsson S et al.
Cell, 2020
SPOP Deregulation Improves the Radiation Response of Prostate Cancer Models by Impairing DNA Damage Repair.
El Bezawy R et al.
Cancers, 2020
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J et al.
The Journal of Clinical Investigation, 2020
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q et al.
Molecular Cancer, 2019
SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOG.
Tan P et al.
Cell Death & Disease, 2019
Japanese Case of Enzalutamide-Resistant Prostate Cancer Harboring a SPOP Mutation With Scattered Allelic Imbalance: Response to Platinum-Based Therapy.
Watanabe K et al.
Clinical Genitourinary Cancer, 2019
The E3 ligase adaptor molecule SPOP regulates fetal hemoglobin levels in adult erythroid cells.
Lan X et al.
Blood Advances, 2019
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2018
SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG.
Shoag J et al.
The Journal of Clinical Investigation, 2018
Identification of SPOP related metabolic pathways in prostate cancer.
Yan M et al.
Oncotarget, 2017
Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.
Janouskova H et al.
Nature Medicine, 2017
Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Wang H et al.
Journal of Translational Medicine, 2017
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.
Mikhaylenko DS et al.
Current Genomics, 2017
Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X et al.
Plos Genetics, 2017
SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing.
Zhu K et al.
Nucleic Acids Research, 2017
Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.
An J et al.
Molecular Cell, 2015
SPOP mutation leads to genomic instability in prostate cancer.
Boysen G et al.
Elife, 2015
Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
Theurillat JP et al.
Science (new York, N.y.), 2014
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Geng C et al.
Cancer Research, 2014
Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P et al.
Human Mutation, 2014
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
An J et al.
Cell Reports, 2014
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C et al.
Proceedings of the National Academy of Sciences of the United States of America, 2013
Speckle-type POZ protein mutations interrupt tumor suppressor function of speckle-type POZ protein in prostate cancer by affecting androgen receptor degradation.
Lai J et al.
Asian Journal of Andrology, 0